{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:57:10Z","timestamp":1791233830415,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eclinm.2026.103978","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:18:29Z","timestamp":1779808709000},"page":"103978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in China"],"prefix":"10.1016","volume":"96","author":[{"given":"Mengyang","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongjun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0109-6951","authenticated-orcid":false,"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.103978_bib1","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.juro.2012.06.020","article-title":"The clinical epidemiology of urachal carcinoma: results of a large, population based study","volume":"188","author":"Bruins","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eclinm.2026.103978_bib2","first-page":"E57","article-title":"Management of urachal cancer: a consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada","volume":"14","author":"Hamilou","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eclinm.2026.103978_bib3","doi-asserted-by":"crossref","first-page":"221.e1","DOI":"10.1016\/j.urolonc.2024.03.011","article-title":"Estimation of the incidence of urachal cancer: a systematic review and meta-analysis of registry-based studies","volume":"42","author":"Olah","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib4","doi-asserted-by":"crossref","DOI":"10.1590\/s1677-5538.ibju.2024.0665","article-title":"Urachal carcinomas: a comprehensive systematic review and meta-analysis","volume":"51","author":"Suartz","year":"2025","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.eclinm.2026.103978_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413315","article-title":"Precision oncology approach for urachal carcinoma: a clinical case report","volume":"25","author":"Juh\u00e1sz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2026.103978_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12081892","article-title":"Urachal carcinoma, an unusual possibility of Hematuria; case report and literature review","volume":"12","author":"Tiutiuc\u0103","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.eclinm.2026.103978_bib7","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.asjsur.2022.10.018","article-title":"Urachal mucinous cystadenocarcinoma: a case report","volume":"46","author":"Peng","year":"2023","journal-title":"Asian J Surg"},{"key":"10.1016\/j.eclinm.2026.103978_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.662589","article-title":"Metastatic urachal carcinoma treated with several different combined regimens: a case report","volume":"11","author":"Zheng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/MOU.0000000000001360","article-title":"Urachal cancer: a clinical, diagnostic, and therapeutic update","volume":"36","author":"Reis","year":"2026","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eclinm.2026.103978_bib10","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/14796694.2025.2516901","article-title":"A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumours (SMART) - design and rationale","volume":"21","author":"Kydd","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib11","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14796694.2025.2497719","article-title":"E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumours-design and rationale","volume":"21","author":"Chandran","year":"2025","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.103978_bib12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4143\/crt.2024.1231","article-title":"A multicenter phase II study of modified FOLFIRINOX for first-line treatment for advanced urachal cancer (ULTIMA; KCSG GU20-03)","volume":"58","author":"Park","year":"2026","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.eclinm.2026.103978_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115204","article-title":"Stromal reprogramming in urachal cancer: fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance","volume":"163","author":"Ma","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.eclinm.2026.103978_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41698-024-00795-4","article-title":"Comprehensive analysis of targetable mutations and tumour microenvironment in urachal cancer","volume":"9","author":"Benjamin","year":"2025","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib15","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1200\/JCO.22.01450","article-title":"Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an Open-label, single-arm, phase II study","volume":"41","author":"Ding","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","article-title":"Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy","volume":"18","author":"Dai","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s12916-025-04250-4","article-title":"Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial","volume":"23","author":"Ji","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.eclinm.2026.103978_bib18","article-title":"Efficacy and safety of camrelizumab plus apatinib for solid tumours: a meta-analysis","volume":"16","author":"Yu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2026.103978_bib19","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.humpath.2015.07.021","article-title":"Urachal carcinoma: a pathologic and clinical study of 46 cases","volume":"46","author":"Dhillon","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eclinm.2026.103978_bib20","article-title":"Comprehensive molecular characterization of urachal adenocarcinoma reveals commonalities with colorectal cancer, including a hypermutable phenotype","volume":"1","author":"Kardos","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1199395","article-title":"Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eclinm.2026.103978_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.urolonc.2016.04.012","article-title":"Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases","volume":"34","author":"Szarvas","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib23","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/01.ju.0000054646.49381.01","article-title":"Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience","volume":"169","author":"Siefker-Radtke","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eclinm.2026.103978_bib24","article-title":"Treatment outcome of different chemotherapy in patients with relapsed or metastatic malignant Urachal tumour","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib25","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.23.02233","article-title":"Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced\/metastatic genitourinary tumours","volume":"42","author":"Apolo","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106858","article-title":"Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression","volume":"88","author":"Cai","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.eclinm.2026.103978_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(24)00203-1","article-title":"Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study","volume":"25","author":"Yu","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.15430\/JCP.2023.28.3.106","article-title":"Effectiveness and safety of apatinib plus programmed cell death protein 1 blockades for patients with treatment-refractory metastatic colorectal cancer: a retrospective exploratory study","volume":"28","author":"Li","year":"2023","journal-title":"J Cancer Prev"},{"issue":"385","key":"10.1016\/j.eclinm.2026.103978_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumour immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eclinm.2026.103978_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0640","article-title":"Low-dose apatinib optimizes tumour microenvironment and potentiates antitumour effect of PD-1\/PD-L1 blockade in lung cancer","volume":"7","author":"Zhao","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.eclinm.2026.103978_bib32","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.103978_bib33","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/0008-5472.CAN-17-2176","article-title":"Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer","volume":"78","author":"Meder","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.eclinm.2026.103978_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41392-025-02153-7","article-title":"Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial","volume":"10","author":"Liu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eclinm.2026.103978_bib35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41392-024-01773-9","article-title":"First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eclinm.2026.103978_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","article-title":"Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eclinm.2026.103978_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105222","article-title":"Efficacy and safety of apatinib in recurrent\/metastatic nasopharyngeal carcinoma: a pilot study","volume":"115","author":"Huang","year":"2021","journal-title":"Oral Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000696","article-title":"Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial","volume":"8","author":"Liu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.eclinm.2026.103978_bib39","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.20.01920","article-title":"Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Lan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.103978_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf202","article-title":"Carelizumab and rivoceranib for advanced extramammary Paget's disease: an investigator-initiated multicenter, single-arm, phase II trial","volume":"30","author":"Zhang","year":"2025","journal-title":"Oncologist"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026002269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:30:28Z","timestamp":1791232228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026002269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"alternative-id":["S2589537026002269"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103978","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in China","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.103978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103978"}}